FDA. Guidance For Industry. Investigator Responsibilities – Protecting The Rights, Safety, And Welfare Of Study Subjects.
I. INTRODUCTION
This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.
This guidance provides an overview of the responsibilities of a person who conducts a clinical investigation of a drug, biological product, or medical device (an investigator as defined in 21 CFR 312.3(b) and 21 CFR 812.3(i)). The goal of this guidance is to help investigators better meet their responsibilities with respect to protecting human subjects and ensuring the integrity of the data from clinical investigations. This guidance is intended to clarify for investigators and sponsors FDA’s expectations concerning the investigator’s responsibility (1) to supervise a clinical study in which some study tasks are delegated to employees or colleagues of the investigator or other third parties and (2) to protect the rights, safety, and welfare of study subjects.
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
Authors:
Center for Drug Evaluation and Research
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research
OCTOBER 2009
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
on demandACROSS Global Training AcademyOnline
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
Prossimi studi clinici
-
National Institute of Medical Sciences and Nutrition...Non ancora reclutamentoRhA - Artrite reumatoide
-
Institute of Liver and Biliary Sciences, IndiaNon ancora reclutamentoInsufficienza epatica acuta su cronicaIndia
-
Centre Leon BerardNon ancora reclutamentoTumore gastrico | Cancro della giunzione esogastricaFrancia
-
TC Erciyes UniversityReclutamentoMalattia endodonticaTacchino
-
Casa di Cura Privata 'Malzoni - Villa dei Platani...ReclutamentoChirurgia | Endometriosi profondaItalia
-
Assembly BiosciencesNon ancora reclutamentoHerpes genitale ricorrente tipo 2Nuova Zelanda
-
Cerenovus, Part of DePuy Synthes Products, Inc.Non ancora reclutamentoIctus ischemico acutoStati Uniti
-
Pamukkale UniversityNon ancora reclutamentoVescica urinaria, iperattivaTacchino
-
China-Japan Friendship HospitalNon ancora reclutamentoObesità | Diabete | Calcoli biliari | Stasi Biliare
-
AstraZenecaDaiichi SankyoNon ancora reclutamentoCancro al seno metastatico | Cancro al seno HER2-positivo | Cancro al seno non resecabile | Cancro al seno a bassa espressione di HER2Canada
-
Chinese University of Hong KongReclutamento
-
Central Hospital, Nancy, FranceNon ancora reclutamento